Trial Profile
Phase II, single-arm study of AZD1775 in combination with paclitaxel, in advanced gastric adenocarcinoma patients harboring TP53 mutation as a second-line chemotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Jun 2022
Price :
$35
*
At a glance
- Drugs Adavosertib (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 13 Jun 2022 Status changed from recruiting to completed.
- 17 May 2019 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.
- 17 May 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.